Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.01 - $3.31
Previous CloseN/A
Volume148.24K
Average Volume (3M)881.05K
Market Cap
$442.53M
Enterprise Value$108.62M
Total Cash (Recent Filing)$300.66M
Total Debt (Recent Filing)$49.42M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Nov 05, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding283,670,140
10 Day Avg. Volume1,262,675
30 Day Avg. Volume881,049
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue25.89
Enterprise Value/Gross Profit222.13
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$3.25Price Target Upside108.33% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementsErasca advanced two key RAS-targeting programs into first-in-human studies, marking an important step for the company’s clinical pipeline.
Scientific And Clinical PotentialThe advancement of both ERAS-0015 and ERAS-4001 into the clinic strengthens conviction in Erasca’s dual-modality RAS strategy and increases the probability of at least one of these programs establishing clinical proof-of-concept.
Strategic PartnershipsErasca is pursuing partnership opportunities for naporafenib, a strategic decision expected to enhance its development and commercialization efforts.
Bears Say
Competitive Market ChallengesErasca faces an increasingly competitive market for molecular glue assets, leading to a reduction in peak market share expectations for its key assets.
Development And Approval DelaysInitial clinical data for ERAS-0015 and ERAS-4001 is not expected until 2026, delaying clarity on their clinical profiles and registrational path opportunity.
Investment OpportunitiesThere are currently seen as better investment opportunities elsewhere in the coverage compared to ERAS shares.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.01 and its highest was $3.31 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $442.53M.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Nov 05, 2025 which is in 50 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Aug 12, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.116 by -$0.004.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.1.
How many shares outstanding does Erasca have?
Erasca has 283,670,140 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.116. Following the earnings report the stock price went up 3.846%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
Erasca Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.25 (108.33% Upside)
$3.25 (108.33% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.01%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
-15.28%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$3.25
▲(108.33% Upside)
Technical Analysis
Checkpoint Therapeutics
―
Eton Pharmaceuticals
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Sana Biotechnology
―
Ownership Overview
22.58% Insiders
10.53% Mutual Funds
0.05% Other Institutional Investors
58.42% Public Companies and
Individual Investors